FMP
Enter
API Tools
Extras
2seventy bio, Inc.
TSVT
NASDAQ
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.
4.99 USD
0 (0%)
Retained Earning Schedule
Year
2024
2023
2022
2021
Retained Earnings (Previous Year)
-511.22M
-293.65M
-39.49M
0
Net Income
-57.25M
-217.57M
-254.14M
-276.21M
Stock Repurchases
0
0
0
0
Dividend Paid
0
0
0
0
Retained Earnings
-568.46M
-511.22M
-293.65M
-39.49M
Other Distributions
-57.25M
-217.57M
-254.15M
-39.49M
All figures are in USD.
